Home

enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the...

Daniel Carlson -
0
TW's Take: solid news in that the market potential is FAR greater here. NVNO is a leader in this space and I have high...
Read more

Trading Alert, Sept. 15th, 2022

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic...

Daniel Carlson -
0
TW's Take: LP-184 continues to show interesting results in many different types of cancer. Can't wait to see this get into clinical trials. DALLAS--(BUSINESS WIRE)-- Lantern...
Read more

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center &...

Daniel Carlson -
0
TW's Take: we are very excited to learn more about this program and this event could be a very nice catalyst for the stock. SAN...
Read more

Moving Day

Daniel Carlson -
15
At The Masters golf tournament, day three of the event is often referred to as "Moving Day". This is the time at which the...
Read more

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at...

Daniel Carlson -
1
TW's Take: this is excellent news as it confirms the benefits of thin film freezing in Voriconazole, ie reduced toxicity, better efficacy. As VORI...
Read more

Don’t Fight The FED. TW’s August Recap.

Daniel Carlson -
0
Sometimes you get it right. Here's what I said in my last July newsletter, as I previewed August. Overall, I continue to be very optimistic...
Read more

The Bear Returns

Daniel Carlson -
9
After a head-fake rally heading into Chairman Powell's long-awaited annual FEC policy speech in Jackson Hole, markets came to the realization that the FED...
Read more

Spectra7 Announces Upsizing of Convertible Debenture Financing to $9.0 Million

Daniel Carlson -
0
TW's Take: we view this as positive in that when most deals are upsized, it's because of overdemand. Once this financing is over, SPVNF...
Read more

When News Is Good

Daniel Carlson -
0
TW turned in a very strong performance last week, with our accounts up 4% relative to a loss of 2% in the S&P 500...
Read more

Trading Alert, August 18th, 2022

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

Daniel Carlson -
0
TW's Take: very exciting hire and commentary about what the future holds for enVVeno. Key points, "first-in-class device" and "multiple clinical trials over the...
Read more

CAR-T Trial Launches…An Interview With Dr. Amit Kumar, CEO of Anixa

Daniel Carlson -
1
TW Research (TW) - First off, congrats on dosing your first patient in your Ovarian cancer trial. It took a lot longer than expected...
Read more

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial

Daniel Carlson -
0
TW's Take: very exciting news as Anixa now has a second potentially blockbuster program in the clinic. CER-T results are expected to be released...
Read more

Pendulum Swings

Daniel Carlson -
5
Market movements are similar to the arc of a pendulum. They swing way past fair value in one direction only to see the inertia...
Read more

Movano Expands Go-To-Market Team with Vice President of UX and UI and Vice President...

Daniel Carlson -
0
TW's Take: building out the go-to-market team. All systems go as we await the game-changing glucose monitoring data later this year. PLEASANTON, Calif., Aug. 11, 2022 /PRNewswire/...
Read more

Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring in Initial Hypoxia...

Daniel Carlson -
0
TW's Take: Movano is executing on their plan to bring industry-leading technology to market at a reasonable cost. Their data continually achieves best in...
Read more

The Domino Effect

Daniel Carlson -
11
This week, in what was a somewhat nostalgic moment for me, Cryoport (CYRX)'s earnings hit the newswire. For long time readers of TW, you...
Read more

Trading Alert, August 5th, 2022

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Trading Alert, August 2nd, 2022

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.